Back to top
more

IceCure Medical (ICCM)

(Delayed Data from NSDQ)

$0.89 USD

0.89
381,125

-0.01 (-1.10%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $0.88 -0.01 (-1.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Viatris (VTRS) delivered earnings and revenue surprises of +10.71% and +2.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Labcorp Holdings (LH) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Labcorp (LH) delivered earnings and revenue surprises of +5.07% and +1.14%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -12.50% and 1.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Natera (NTRA) delivered earnings and revenue surprises of 15.25% and 13.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IceCure Medical Stock Dips Despite Positive ICESECRET Study Results

by Zacks Equity Research

ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.

Zacks Equity Research

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

IceCure Medical (ICCM) delivered earnings and revenue surprises of -14.29% and 5.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -17.24% and 20.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Dare Bioscience (DARE) delivered earnings and revenue surprises of 8.33% and 98.64%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Surgery Partners (SGRY) Misses Q3 Earnings Estimates

by Zacks Equity Research

Surgery Partners (SGRY) delivered earnings and revenue surprises of -24% and 0.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 15.38% and 7.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alignment HealthCare Partners With Intermountain Health in Nevada

by Zacks Equity Research

ALHC partners with Intermountain Health to enhance access to high-quality care for Medicare members in Clark and Washoe counties, starting Jan 2025.

Zacks Equity Research

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

by Zacks Equity Research

Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic have been highlighted in this Screen of The Week article.

Sanghamitra Saha headshot

Bet on 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Adverum Biotechnologies (ADVM), IceCure Medical (ICCM), DarioHealth (DRIO), Energous (WATT) and Virgin Galactic (SPCE).

Zacks Equity Research

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

IceCure Medical (ICCM) delivered earnings and revenue surprises of 14.29% and 12.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

60 Degrees Pharmaceuticals Inc. (SXTP) delivered earnings and revenue surprises of -6.82% and 13.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx (GDRX) delivered earnings and revenue surprises of -11.11% and 0.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Charles River Laboratories (CRL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Charles River (CRL) delivered earnings and revenue surprises of 17.15% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Progyny (PGNY) Beats Q2 Earnings Estimates

by Zacks Equity Research

Progyny (PGNY) delivered earnings and revenue surprises of 19.44% and 1.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

by Zacks Equity Research

IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."

Zacks Equity Research

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

by Zacks Equity Research

IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields

Zacks Equity Research

IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Doximity (DOCS) delivered earnings and revenue surprises of 25% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ReWalk Robotics (LFWD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ReWalk (LFWD) delivered earnings and revenue surprises of -4.29% and 4.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

The Oncology Institute (TOI) delivered earnings and revenue surprises of -83.33% and 0.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DocGo Inc. (DCGO) Matches Q1 Earnings Estimates

by Zacks Equity Research

Motion Acquisition (DCGO) delivered earnings and revenue surprises of 0% and 3.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?